Cancer is crafty. When one avenue driving its growth is blocked by drugs targeting that path, the malignancy often creates a detour, finding an alternative route to get around the roadblock.
Jun 14, 2011
0
1
Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation ...
Jul 19, 2018
0
26
In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.
Aug 8, 2016
0
7
Prostate cancer is the most common cancer among men in the United States. Many patients can live long lives due to early detection and treatment with androgen deprivation therapy. However, despite the benefits of this therapy, ...
Jun 15, 2022
0
84
Researchers believe they have discovered one reason why some women with estrogen receptor-positive breast cancer may respond poorly or only temporarily to estrogen-blocking drugs such as tamoxifen. Results of a new study, ...
Jun 23, 2014
0
0
Over the last decade, enzalutamide and similar drugs have led to significant tumor control and increased survival time for men who have metastatic prostate cancer that continues to grow despite treatments to reduce male hormone ...
Apr 27, 2020
0
70
By taking a lesson from prostate cancer, researchers now have a promising lead on a treatment for COVID-19.
Dec 21, 2020
0
110
Polycystic ovarian syndrome, or PCOS, can cause a range of symptoms, including disrupted menstrual cycles, abdominal obesity, cardiovascular disease, and type 2 diabetes. It's also one of the biggest causes of infertility—in ...
Apr 18, 2023
0
14
At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link between androgen receptors—which bind to hormones like testosterone—and SARS-CoV-2 ...
Aug 18, 2023
0
36
A research paper published today in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator that stimulates the male sex hormone receptor, has anti-tumor effects in estrogen receptor-positive ...
Feb 8, 2024
0
34
